

# Real-World Outcomes of Upfront Abiraterone in Metastatic Castration-Sensitive Prostate Cancer Patients at a Tertiary Care Hospital

Muhammad Awais Majeed, Ayesha Alam, Maryam Imran, Shakeel Muzaffar, Muhammad Ahsan Jamil, Noor Ul Ain, Muhammad Usman Shabbir, Umer Salman, Sameen Bin Naeem

Shaukat Khanum Memorial Cancer Hospital and Research Centre, Medical Oncology, Lahore, Pakistan.

## OBJECTIVE

To assess the real-world efficacy of upfront abiraterone treatment on overall survival (OS) and progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer in our population.

## RESULTS

The cohort demonstrated a median progression-free survival (PFS) of 20.7 months and a median overall survival (OS) of 38.4 months. These outcomes represent the entire study population, irrespective of subgroup classification. Different subgroup analyses do not show any statistically significant difference.




FIGURE 2: Overall survival in months from the commencement of therapy to the date of death or last follow-up

## METHODS

This retrospective study involved 47 adult patients aged 40 years and older. It focused exclusively on patients who were presented with de novo metastatic castration-sensitive disease and were treated with upfront abiraterone acetate. The study was carried out at the Department of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. Patient data spanning 10 years, from 2014 to 2024, was collected from hospital records.




FIGURE 1: Progression-free survival in months from the commencement of abiraterone

## Baseline Clinical Characteristics of the Study Cohort

The study included 47 patients. Among them, 14 patients (29.8%) had low-volume disease, while 33 patients (70.2%) presented with high-volume disease. Visceral metastases were observed in 13 patients (27.7%), and 21 patients (44.7%) had bone-only disease. Nodal metastases were present in 33 patients (70.2%). Regarding Gleason scores, 12 patients (25.5%) had a score less than 8, while 35 patients (74.5%) had a score of 8 or above. Based on PSA levels, 30 patients (63.8%) had values less than 100 ng/mL, whereas 17 patients (36.2%) had PSA levels equal to or greater than 100 ng/mL.

## CONCLUSION

The study concludes that the real-world outcomes of upfront abiraterone in mCSPC are lower within our population than those observed in clinical trials. Additionally, there was no statistically significant difference between subgroups in our study. To confirm these findings and better understand which patient populations may derive the most benefit from this treatment, future research with larger, preferably prospective, cohorts is necessary.